A Phase 2 interventional study of Metformin and doxycycline in Acne Vulgaris, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Recruiting at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to compare the effect of doxycycline and metformin in treatment of acne vulgaris patients. The main question is aimed to answer is whether metformin is more effective than doxycycline in treatment of acne vulgaris patient or not.
Patients will be asked to take doxycycline along with tropical treatment in one group and metformin along with tropical treatment in another group.
Researcher will compare the clinical improvement in two groups.
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's planned enrollment of 120 is above the median of 69 across 628 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh is the lead sponsor of 126 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Newly diagnosed moderate and severe AV patients diagnosed by a dermatologist
-
Exclusion Criteria:
Metformin 500 mg twice daily along with topical retinoids for 12 weeks
Drug: Metformin and doxycycline
Doxycycline 100 mg twice daily along with topical retinoids for 12 weeks
Drug: Metformin and doxycycline
Metformin 500 mg tablet twice daily
Global Acne Grading System (GAGS) Score
Acne Vulgaris Severity assesment by GAGS score
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh